MA32274B1 - Thérapie antivirale - Google Patents

Thérapie antivirale

Info

Publication number
MA32274B1
MA32274B1 MA33258A MA33258A MA32274B1 MA 32274 B1 MA32274 B1 MA 32274B1 MA 33258 A MA33258 A MA 33258A MA 33258 A MA33258 A MA 33258A MA 32274 B1 MA32274 B1 MA 32274B1
Authority
MA
Morocco
Prior art keywords
antiviral therapy
antiviral
therapies
relates
present
Prior art date
Application number
MA33258A
Other languages
Arabic (ar)
English (en)
Inventor
Witold Filipowicz
Markus Heim
Magdalena Sarasin-Filipowicz
Francois H T Duong
Edward Oakeley
Original Assignee
Novartis Forschungsstiftung
Univ Hospital Basel
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Forschungsstiftung, Univ Hospital Basel filed Critical Novartis Forschungsstiftung
Publication of MA32274B1 publication Critical patent/MA32274B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/15—Medicinal preparations ; Physical properties thereof, e.g. dissolubility
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/576—Immunoassay; Biospecific binding assay; Materials therefor for hepatitis
    • G01N33/5767—Immunoassay; Biospecific binding assay; Materials therefor for hepatitis non-A, non-B hepatitis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Analytical Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Communicable Diseases (AREA)
  • General Physics & Mathematics (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Cell Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

L'invention porte sur des traitements pour l'amélioration de thérapies antivirales et sur un procédé pour déterminer si des thérapies antivirales seront ou non efficaces. En particulier, la présente invention porte sur un procédé pour la détermination de la probabilité qu'un sujet ayant une infection virale du foie soit sensible à une thérapie antivirale qui comprend la stimulation de l'activité des interférons (ifn). L'invention porte également sur des coffrets pour effectuer ladite détermination.
MA33258A 2008-04-21 2010-10-15 Thérapie antivirale MA32274B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP08154878 2008-04-21
PCT/EP2009/054641 WO2009130176A1 (fr) 2008-04-21 2009-04-20 Thérapie antivirale

Publications (1)

Publication Number Publication Date
MA32274B1 true MA32274B1 (fr) 2011-05-02

Family

ID=39830378

Family Applications (1)

Application Number Title Priority Date Filing Date
MA33258A MA32274B1 (fr) 2008-04-21 2010-10-15 Thérapie antivirale

Country Status (16)

Country Link
US (1) US20110117563A1 (fr)
EP (1) EP2271776A1 (fr)
JP (1) JP2011519551A (fr)
KR (1) KR20110014979A (fr)
CN (1) CN102016072A (fr)
AU (1) AU2009240021B2 (fr)
BR (1) BRPI0910534A2 (fr)
CA (1) CA2719078A1 (fr)
IL (1) IL208351A0 (fr)
MA (1) MA32274B1 (fr)
MX (1) MX2010011587A (fr)
NZ (1) NZ588144A (fr)
RU (1) RU2010146701A (fr)
SG (1) SG190570A1 (fr)
WO (1) WO2009130176A1 (fr)
ZA (1) ZA201006647B (fr)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2473636T3 (en) * 2009-09-03 2017-02-06 Medimmune Llc TYPE 1 INTERFERON DIAGNOSTICS
CA2780044A1 (fr) * 2009-11-14 2011-05-19 F. Hoffmann-La Roche Ag Marqueurs biologiques destines a predire une reaction rapide au traitement du virus de l'hepatite c (hcv)
US9709565B2 (en) 2010-04-21 2017-07-18 Memed Diagnostics Ltd. Signatures and determinants for distinguishing between a bacterial and viral infection and methods of use thereof
CA2863819C (fr) 2012-02-09 2021-11-23 Memed Diagnostics Ltd. Signatures et determinants pour diagnostiquer des infections et procedes d'utilisation de ceux-ci
CN103740755A (zh) * 2013-12-23 2014-04-23 中国农业大学 猪ifit1基因在抗prrs病毒中的应用
CA3190715A1 (fr) 2014-08-14 2016-02-18 Memed Diagnostics Ltd. Analyse computationnelle de donnees biologiques au moyen d'un collecteur et d'un hyperplan
WO2016059636A1 (fr) 2014-10-14 2016-04-21 Memed Diagnostics Ltd. Signatures et déterminants pour diagnostiquer des infections chez des sujets non humains et leurs procédés d'utilisation
EP3423590A4 (fr) 2016-03-03 2020-02-26 Memed Diagnostics Ltd. Déterminants d'arn pour différencier des infections bactériennes d'infections virales
WO2018011796A1 (fr) 2016-07-10 2018-01-18 Memed Diagnostics Ltd. Diagnostic précoce d'infections
CN109661578B (zh) 2016-07-10 2022-05-10 米密德诊断学有限公司 用于区分细菌和病毒感染的蛋白质特征
EP3519833B1 (fr) 2016-09-29 2024-08-14 MeMed Diagnostics Ltd. Méthodes de pronostic et de traitement
US11353456B2 (en) 2016-09-29 2022-06-07 Memed Diagnostics Ltd. Methods of risk assessment and disease classification for appendicitis
US10209260B2 (en) 2017-07-05 2019-02-19 Memed Diagnostics Ltd. Signatures and determinants for diagnosing infections and methods of use thereof

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050123938A1 (en) * 1999-01-06 2005-06-09 Chondrogene Limited Method for the detection of osteoarthritis related gene transcripts in blood
US20080161203A1 (en) * 2006-12-27 2008-07-03 Su Chun-Lin Markers identified for liver fibrosis and cirrhosis and the microarray panel thereof

Also Published As

Publication number Publication date
SG190570A1 (en) 2013-06-28
MX2010011587A (es) 2011-05-03
KR20110014979A (ko) 2011-02-14
AU2009240021B2 (en) 2013-01-10
NZ588144A (en) 2012-04-27
IL208351A0 (en) 2010-12-30
WO2009130176A9 (fr) 2010-01-07
BRPI0910534A2 (pt) 2015-09-29
RU2010146701A (ru) 2012-05-27
AU2009240021A1 (en) 2009-10-29
US20110117563A1 (en) 2011-05-19
CA2719078A1 (fr) 2009-10-29
EP2271776A1 (fr) 2011-01-12
JP2011519551A (ja) 2011-07-14
WO2009130176A1 (fr) 2009-10-29
CN102016072A (zh) 2011-04-13
ZA201006647B (en) 2011-05-25

Similar Documents

Publication Publication Date Title
MA32274B1 (fr) Thérapie antivirale
Fidock et al. The innate immune response, clinical outcomes, and ex vivo HCV antiviral efficacy of a TLR7 agonist (PF‐4878691)
Merat et al. Seroprevalence of hepatitis C virus: the first population-based study from Iran
Grint et al. Temporal changes and regional differences in treatment uptake of hepatitis C therapy in EuroSIDA
IL181629A0 (en) Compositions and methods for the diagnosis and tretment of tumor
NO20056236L (no) Behandling med anti-VEGF-antistoffer
Sun et al. Randomised clinical trial: efficacy of peginterferon alfa‐2a in HBeAg positive chronic hepatitis B patients with lamivudine resistance
ATE396731T1 (de) Thiazole zur verwendung als inhibitoren von protein-kinasen
EA201190042A1 (ru) Имидазопиразиновые ингибиторы тирозинкиназы syk
MY191929A (en) The use of inhibitors of bruton's tyrosine kinase (btk)
WO2006083289A3 (fr) Methodes et compositions ameliorant l'immunite par depletion in vivo de l'activite cellulaire immunosuppressive
WO2013049770A3 (fr) Méthodes de traitement du cancer
SG151327A1 (en) Deazapurines useful as inhibitors of janus kinases
WO2006002437A3 (fr) Traitement d'etats pathologiques impliquant la demyelinisation
NZ629273A (en) Compositions and methods for the treatment of infections and tumors
NO20044462L (no) Anvendelse av EP4-reseptorligander i behandling av IL-6 involverte sykdommer
TW200637574A (en) Treatment method
EA201001695A1 (ru) Применение эпотилона d для лечения заболеваний, связанных с тау-белком
WO2004071430A3 (fr) Ciblage iarn de virus
Terao et al. Depletion of CD38‐positive regulatory T cells by anti‐CD38 monoclonal antibodies induces a durable response to SARS‐CoV‐2 vaccination in patients with plasma cell dyscrasia
EA201200329A3 (ru) Ингибиторы мет для повышения эффективности лучевой терапии
WO2010001369A3 (fr) Méthodes pour le traitement et le diagnostic du cancer
WO2010065536A3 (fr) Antigène-2 du stroma de la moelle osseuse recombinant dans le traitement de maladies auto-immunes
WO2002080960A3 (fr) Neuropathologies associees a l'expression du tnf-$g(a)
Borgia et al. Increased eligibility for treatment of chronic hepatitis C infection with shortened duration of therapy: Implications for access to care and elimination strategies in Canada